SWG Educational Activities
Meetings
EHA SWG EWALL Symposium
Location and date
This meeting was held in Frankfurt in June 2023 as part of EHA2023.
Topic
Personalized ALL therapy.
Chair
Nicola Gokbuget
Sessions and speakers
- B-cell precursor ALL, the Finnish experience (Kimmo Porkka).
- B-cell precursor ALL, the Italian experience (Giovanni Roti).
- T-ALL, the French experience (Vahid Asnafi).
- The US experience (Sarah Tasian).
Clinical trials involving the SWG
EWALL-INO study
Full title
‘Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL).’
Status
Ongoing.
Chair
P Rousselot
EWALL-Ph-03 study
Full title
‘An open-label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).’
Status
Ongoing.
Chair
Oliver Ottmann
ACCADEMIA trial for B-cell precursor ALL in adults
Full title
‘Randomized Controlled Phase 3 Trial Comparing Standard of Care versus Standard of Care with Components Replaced by Subcutaneous Blinatumomab for Remission Induction and Consolidation Therapy of Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (ACCADEMIA Study).’
Promoter
GIMEMA, on behalf of HOVON, UK-NCRI, and PETHEMA.
Status
In development.
Collaborations on international projects
- Development of an EWALL guideline for the diagnosis and management of adult ALL.
- Development of a robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia.
- Grants received by networks or principal investigators.
Back